PHS
OCUL icon

PFM Health Sciences’s Ocular Therapeutix OCUL Stock Holding History

PFM Health Sciences’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-402,843
Closed -$3.5M – 99
2024
Q3 		$3.5M Buy
+402,843
New +$3.32M 0.2% 57

Other funds holding OCUL

SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PFM Health Sciences's OCUL Position: Q4 2024 in Review

PFM Health Sciences sold out of Ocular Therapeutix (OCUL) in Q4 2024, closing a stake of 402,843 shares — an estimated $3.5M sold.

PFM Health Sciences first reported a position in OCUL in Q3 2024 and held it in 1 quarter. The position peaked at $3.5M in Q3 2024. 179 funds tracked by Wall St. Rank hold OCUL as of Q4 2024.

  • PFM Health Sciences reported no remaining Ocular Therapeutix position as of Q4 2024 after selling out during the quarter.
  • PFM Health Sciences sold 402,843 Ocular Therapeutix shares in Q4 2024, an estimated $3.5M.
  • PFM Health Sciences first reported a position in Ocular Therapeutix in Q3 2024 and held it in 1 quarter.
  • PFM Health Sciences's Ocular Therapeutix position peaked at $3.5M in Q3 2024.
  • 179 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2024.

Based on PFM Health Sciences's 13F filing for Q4 2024, filed 14 Feb 2025.